Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 8:14:1191912.
doi: 10.3389/fimmu.2023.1191912. eCollection 2023.

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia

Mohammad Hassan Hodroj  1 , Iman Abou Dalle  1   2 , Nour Moukalled  1   2 , Jean El Cheikh  1   2 , Mohamad Mohty  3 , Ali Bazarbachi  1   2
Affiliations
Review

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia

Mohammad Hassan Hodroj et al. Front Immunol. .

Abstract

The outcome of B-cell acute lymphoblastic leukemia (B-ALL) has improved over time with the incorporation of multi-agent chemotherapy in the treatment landscape as well as the recent approval of immunotherapeutic agents allowing a larger proportion of patients to undergo allogeneic hematopoietic cell transplantation (allo-HCT) which is still considered a potential curative approach. However, relapse post-transplant is still occurring and constitutes a common cause of treatment failure in B-ALL. The present review aims to discuss the novel strategies and therapies used to prevent and overcome relapse post allo-HCT in patients with ALL, focusing on the role of tyrosine kinase inhibitors in Philadelphia chromosome positive B-ALL, the role of innovative agents such as blinatumomab and inotuzumab ozogamicin, and finally the role of cellular therapy.

Keywords: acute lymphoblastic leukemia; allogeneic stem cell transplant; antibody drug conjugates; bispecific antibodies; relapse; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Treat options Oncol (2019) 20(1):4. doi: 10.1007/s11864-019-0603-z - DOI - PMC - PubMed
    1. Künz T, Hauswirth AW, Hetzenauer G, Rudzki J, Nachbaur D, Steiner N. Changing landscape in the treatment of adult acute lymphoblastic leukemia (ALL). Cancers (Basel) (2022) 14(17). doi: 10.3390/cancers14174290 - DOI - PMC - PubMed
    1. Kegyes D, Jitaru C, Ghiaur G, Ciurea S, Hoelzer D, Tomuleasa C, et al. . Switching from salvage chemotherapy to immunotherapy in adult b-cell acute lymphoblastic leukemia. Blood Rev (2023), 101042. doi: 10.1016/j.blre.2023.101042 - DOI - PubMed
    1. Rijneveld AW, van der Holt B, SM D, BJ B, de Weerdt O, Muus P, et al. . Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia (2011) 25(11):1697–703. doi: 10.1038/leu.2011.141 - DOI - PubMed
    1. Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol (2020) 11:2040620720910023. doi: 10.1177/2040620720910023 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources